SciBase receives additional order from Castle Biosciences, advancing the collaboration
SciBase received an additional order valued at approximately $0.6 million to accelerate its ongoing clinical study and prepare for a second study under its collaboration with Castle Biosciences. The order includes the Nevisense Go pen device and electrodes, with deliveries expected to begin in Q4 2026.
Key figures
- Delivery quarter
- Q4 2026
- Study acceleration
- clinical study acceleration and prep for second study
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.